19 January 2022 | Wednesday | News
Mr. Richard John Daly, President of CARsgen Therapeutics Corporation
Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, business development, commercialization, investor relations and public relations. Mr. Daly will also contribute to the overall growth strategies and business planning of CARsgen, helping the Company to develop more innovative cell therapies to cancer patients worldwide and make cancer curable.
Mr. Daly brings approximately 30 years of experience in pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Mr. Daly served as Chief Operating Officer of Beyond Spring, Inc. (NASDAQ: BYSI). From February 2016 to July 2018, Mr. Daly served as Chief Executive Officer, President and Chairman of Neuralstem, Inc. (NASDAQ: PALI). Mr. Daly served in AstraZeneca as the President of the U.S. Diabetes subsidiary (formerly BMS-AZ Diabetes Alliance). From 1998 to 2011, Mr. Daly served at Takeda and TAP Pharmaceuticals, a joint venture established between Takeda and Abbott Laboratories, holding several leadership positions, including the Executive Vice President at Takeda Pharmaceutical North America and the Senior Vice President of marketing at TAP Pharmaceuticals. Mr. Daly currently sits on the boards of directors of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Opiant Pharmaceuticals (NASDAQ: OPNT).
Mr. Daly holds an MBA from Kellogg School of Management at Northwestern University and a Bachelor of Science degree from University of Notre Dame.
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, "We warmly welcome Mr. Daly to join CARsgen. Mr. Daly is an industry veteran with approximately 30 years of successful experiences in pharmaceutical companies, including leadership positions in multi-national organizations such as Takeda, BMS, and AstraZeneca. The breadth of Mr. Daly's experiences in sales and marketing, business development, and operation management makes him an ideal fit to lead the team of our U.S. subsidiary. Mr. Daly joins us at an exciting time of the company's accelerating growth and development, and it resonates with our ambition for the global markets. The joining of Mr. Daly will further accelerate our international business activities, including clinical development, CMC operation, business development, etc. Together with Mr. Daly and the team, we are committed to developing more innovative cell therapies to cancer patients worldwide and make cancer curable."
Mr. Daly, President of CARsgen Therapeutics Corporation, said, "The unique CARsgen scientific, clinical and manufacturing platform is incredibly exciting and has the potential to deliver improved therapeutic options for cancer patients. I am honored and thrilled to be joining the CARsgen team at this pivotal time and I look forward to working with our talented team to continue to build the platform that can deliver on the CARsgen promise of providing enhanced care for patients and, more importantly, making cancer curable."